Drug Profile
Research programme: alpha synuclein targeted anti-sense oligonucleotides - nLife
Alternative Names: a-syn targeting oligonucleotide - nLife; NLF-PD-1233Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator nLife Therapeutics
- Class Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action Antisense RNA modulators; Synuclein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Parkinson's disease in Spain (Intranasal)
- 25 Apr 2023 Discontinued - Preclinical for Parkinson's disease in Spain (Intrathecal)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in Spain (Intranasal)